Does the media refer more to DNTH or MRNA?

In the previous week, Moderna had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 26 mentions for Moderna and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Moderna's score of 0.53 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Positive

Does the media refer more to DNTH or GMAB?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 3 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.01 beat Genmab A/S's score of 0.72 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Dianthus Therapeutics' score of 1.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNTH or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.64 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or SMMT?

In the previous week, Summit Therapeutics had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 8 mentions for Summit Therapeutics and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Summit Therapeutics' score of 0.39 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Dianthus Therapeutics (DNTH) Competitors

$84.03 +2.46 (+3.02%)

As of 01:21 PM Eastern

Compare

DNTH vs. MRNA, GMAB, ASND, BBIO, and SMMT

Should you buy Dianthus Therapeutics stock or one of its competitors? MarketBeat compares Dianthus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dianthus Therapeutics include Moderna (MRNA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Dianthus Therapeutics compare to Moderna?

Dianthus Therapeutics (NASDAQ:DNTH) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Dianthus Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher earnings, but lower revenue than Moderna. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,251.92	-$162.34M	-$4.13	N/A
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A

Dianthus Therapeutics presently has a consensus target price of $117.82, suggesting a potential upside of 40.21%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 24.63%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Moderna has a net margin of -143.55% compared to Dianthus Therapeutics' net margin of -12,998.50%. Moderna's return on equity of -26.64% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 21 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 26 mentions for Moderna and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Moderna's score of 0.53 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Genmab A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dianthus Therapeutics presently has a consensus price target of $117.82, suggesting a potential upside of 40.21%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 59.70%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 3 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.01 beat Genmab A/S's score of 0.72 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Dianthus Therapeutics' net margin of -12,998.50%. Genmab A/S's return on equity of 15.34% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Genmab A/S	21.05%	15.34%	8.94%

Dianthus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,251.92	-$162.34M	-$4.13	N/A
Genmab A/S	$3.72B	3.98	$963M	$1.32	17.99

Summary

Dianthus Therapeutics beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Dianthus Therapeutics' score of 1.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Dianthus Therapeutics' net margin of -12,998.50%. Ascendis Pharma A/S's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Dianthus Therapeutics currently has a consensus target price of $117.82, suggesting a potential upside of 40.21%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 36.51%. Given Dianthus Therapeutics' higher possible upside, equities analysts plainly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,251.92	-$162.34M	-$4.13	N/A
Ascendis Pharma A/S	$814.57M	16.57	-$258M	$8.67	24.96

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Dianthus Therapeutics (NASDAQ:DNTH) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.64 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a net margin of -124.42% compared to Dianthus Therapeutics' net margin of -12,998.50%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Dianthus Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,251.92	-$162.34M	-$4.13	N/A
BridgeBio Pharma	$502.08M	25.40	-$724.93M	-$3.74	N/A

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dianthus Therapeutics presently has a consensus price target of $117.82, suggesting a potential upside of 40.21%. BridgeBio Pharma has a consensus price target of $89.59, suggesting a potential upside of 37.60%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dianthus Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Dianthus Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Summit Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

Dianthus Therapeutics has higher revenue and earnings than Summit Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,251.92	-$162.34M	-$4.13	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Summit Therapeutics had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 8 mentions for Summit Therapeutics and 5 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat Summit Therapeutics' score of 0.39 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summit Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Summit Therapeutics	N/A	-291.24%	-243.07%

Dianthus Therapeutics currently has a consensus target price of $117.82, suggesting a potential upside of 40.21%. Summit Therapeutics has a consensus target price of $26.05, suggesting a potential upside of 74.62%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Dianthus Therapeutics beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.59B	$3.26B	$6.26B	$12.40B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-20.35	17.82	22.37	24.16
Price / Sales	2,251.92	321.51	547.57	124.65
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	7.36	6.55	9.79	6.69
Net Income	-$162.34M	$24.20M	$3.56B	$336.98M
7 Day Performance	-3.05%	-3.19%	-1.27%	0.45%
1 Month Performance	-3.88%	0.39%	3.58%	4.95%
1 Year Performance	377.71%	46.56%	27.13%	34.01%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.8812 of 5 stars	$84.03 +3.0%	$117.82 +40.2%	+365.3%	$4.59B	$2.04M	N/A	80	Positive News Insider Trade
MRNA Moderna	1.5144 of 5 stars	$47.03 +0.3%	$35.73 -24.0%	+68.7%	$18.60B	$1.94B	N/A	4,700	Trending News
GMAB Genmab A/S	4.0043 of 5 stars	$26.89 +0.1%	$39.07 +45.3%	+9.6%	$16.75B	$3.72B	20.37	3,029	Gap Down
ASND Ascendis Pharma A/S	4.633 of 5 stars	$239.65 -3.0%	$295.39 +23.3%	+23.3%	$15.41B	$814.57M	27.64	1,189	Positive News Short Interest Decrease
BBIO BridgeBio Pharma	3.4898 of 5 stars	$67.73 -2.0%	$88.90 +31.3%	+80.1%	$13.54B	$502.08M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. MRNA, GMAB, ASND, BBIO, and SMMT

How does Dianthus Therapeutics compare to Moderna?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. MRNA, GMAB, ASND, BBIO, and SMMT

How does Dianthus Therapeutics compare to Moderna?

Which has more volatility & risk, DNTH or MRNA?

Do institutionals & insiders have more ownership in DNTH or MRNA?

Which has higher valuation & earnings, DNTH or MRNA?

Do analysts prefer DNTH or MRNA?

Is DNTH or MRNA more profitable?

Does the media refer more to DNTH or MRNA?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Do insiders & institutionals have more ownership in DNTH or GMAB?

Do analysts recommend DNTH or GMAB?

Does the media refer more to DNTH or GMAB?

Is DNTH or GMAB more profitable?

Which has more risk & volatility, DNTH or GMAB?

Which has higher earnings & valuation, DNTH or GMAB?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Does the media refer more to DNTH or ASND?

Is DNTH or ASND more profitable?

Which has more risk and volatility, DNTH or ASND?

Do analysts recommend DNTH or ASND?

Do insiders and institutionals have more ownership in DNTH or ASND?

Which has preferable valuation & earnings, DNTH or ASND?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Does the media favor DNTH or BBIO?

Is DNTH or BBIO more profitable?

Which has preferable earnings & valuation, DNTH or BBIO?

Do insiders & institutionals have more ownership in DNTH or BBIO?

Do analysts rate DNTH or BBIO?

Which has more volatility & risk, DNTH or BBIO?

Summary

How does Dianthus Therapeutics compare to Summit Therapeutics?

Which has more volatility and risk, DNTH or SMMT?

Which has stronger valuation & earnings, DNTH or SMMT?

Do institutionals and insiders have more ownership in DNTH or SMMT?

Does the media refer more to DNTH or SMMT?

Is DNTH or SMMT more profitable?

Do analysts rate DNTH or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools